Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05325580 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 28, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Notable Primary completion date: Aug 1, 2023 to Dec 1, 2025
    • Study completion date: Dec 30, 2023 to Dec 30, 2026
    v5
  2. Minor Enrollment target: 300 to 424v4
  3. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Aug 1, 2022 to Aug 1, 2023
    • Study completion date: Aug 30, 2022 to Dec 30, 2023
    • Start date changed from estimate of Jun 1, 2022 to Dec 1, 2021
    • Site details revised
  4. Notable Phase: Not applicable to Phase 3v2 Show 6 more changesShow less
    • Start date: Nov 1, 2020 to Jun 1, 2022
    • Trial status: Recruiting to Not Yet Recruiting
    • Enrollment target: 310 to 300
    • Primary completion date: Dec 1, 2022 to Aug 1, 2022
    • Study completion date: Jan 30, 2023 to Aug 30, 2022
    • Site details revised
  5. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Intravenous Magnesium Sulfate Vs Placebo to Treat Non -Traumatic Acute Headaches in the Emergency Department
Trial Details
NCT Number NCT05325580
Lead Sponsor University of Monastir
Conditions
(from sponsor)
Head Pain
Related terms Headache
Enrollment 424 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov